Loading...
•
Sep 30, 2021
Ionis Q3 2021 Earnings Report
Ionis reported third quarter 2021 financial results, highlighting strategic advancements and pipeline development.
Key Takeaways
Ionis Pharmaceuticals reported $133 million in total revenues for Q3 2021. The company is well-capitalized with $2 billion in cash and investments. The company is advancing its Phase 3 pipeline and commercial readiness initiatives.
Olezarsen Phase 3 CORE study in patients with sHTG was initiated.
Donidalorsen Phase 2 data is set to be presented at the ACAAI Annual Meeting, with Phase 3 initiation on track for year-end.
Tofersen Phase 3 VALOR study missed the primary endpoint, but signs of reduced disease progression were observed.
Ionis remains on track to achieve its 2021 financial guidance, driven by increased R&D revenue in the fourth quarter.
Revenue by Segment
Forward Guidance
Ionis projects increased R&D revenue and expenses in the fourth quarter of 2021 and remains on track to achieve its 2021 financial guidance.
Positive Outlook
- Increased R&D revenue is expected in Q4 2021.
- Advancement of partnered programs is expected.
- Company is well-capitalized with $2 billion in cash.
- Commercial readiness initiatives are advancing.
- Multiple product launches are anticipated, potentially starting in 2023.
Challenges Ahead
- Increased expenses are projected in Q4 2021.
- Tofersen Phase 3 VALOR study missed primary endpoint.
- The Biogen Phase 3 VALOR study of tofersen in patients with SOD1-ALS did not meet the primary endpoint of change from baseline to week 28 in the ALS Functional Rating Scale-Revised (ALSFRS-R)
- Net loss attributable to Ionis’ common stockholders for the three and nine months ended September 30, 2021 increased compared with the same periods in the prior year
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...